J&J's $35 Abiomed Bonus Puts Half Its Value on a $3.7B Sales Bar, Not the FDA Win

On November 1, 2022, Johnson & Johnson agreed to buy Abiomed, the maker of the tiny Impella heart pump, for $380.00 a share in cash - and then held out a second envelope: up to $35.00 more per share, payable later, if certain things went right.¹ The headlines called it a $16.6 billion deal and moved on. But that number is only the upfront cash; the $35.00 ceiling sits on top of it, unmentioned in most of the coverage.¹ The interesting part of this deal was never the price. It was the shape of the promise stapled to the back of it.

The story you'll read is that Abiomed's sellers got a rich earn-out riding on clinical milestones - an FDA approval, a treatment-guideline win, the kind of scientific hurdles a device company knows how to clear. That framing is comforting because it makes the extra $35 feel like it turns on medicine. Read the actual filing and the emphasis moves. Exactly half the ceiling turns on something far more mundane: whether J&J can move enough boxes.

Half the bonus rides on a sales target, not a science win: the $35 splits three ways, and the largest single slice turns on revenue rather than regulators

Here is what the Schedule 14D-9 actually says. The $35.00 is not one payment; it is three, and they only sum to $35.00 if every one lands on the faster track.³ The largest single piece - $17.50 per CVR, exactly half the ceiling - pays out only if worldwide net sales of Abiomed's products exceed $3.7 billion during a specific measurement window running through J&J's fiscal 2028.³ Miss that window and hit the target later, and the payout doesn't just slip - it is cut clean in half, to $8.75.³ The other two components are the ones the deal was sold on: $7.50 for an FDA approval of Impella in STEMI patients without cardiogenic shock by January 1, 2028, and $10.00 for a specified Class I clinical-guideline recommendation.³⁴ Notice the arithmetic. The single biggest lever is a revenue bar - and revenue, after the deal closes, is J&J's to hit, not the seller's.

That distinction matters more than it looks. A clinical milestone is, in a sense, the seller's home turf - it turns on the product's merits and the evidence a device company like Abiomed spent years building. A sales milestone is different. Once J&J owns the asset, the sales number is a function of J&J's own priorities: how hard its reps push Impella, how it prices it, how it fits the pump into a portfolio full of competing claims on attention. The sellers, cashed out and gone, no longer touch the lever that unlocks the biggest slice of their upside. They handed J&J the wheel and then bet on how well J&J would drive.

Why a contingent right beat simply naming a number: the CVR let both sides sign a deal they disagreed about, by paying only if the optimists turn out right

A contingent value right exists to bridge a disagreement about the future. Abiomed's sellers believed the Impella franchise would grow fast and clear its regulatory and guideline hurdles; J&J was willing to pay for that story only if it came true. Rather than argue the point into a single headline number, they split the difference into a floor and a ceiling: $380.00 that pays no matter what, and up to $35.00 more that pays only if the optimism is vindicated.¹ It is an elegant way to close a gap - both parties get to sign the deal they believe in. But the design choices inside that structure are where the leverage hides, and J&J put the heaviest weight on the one milestone its own execution most controls, with a built-in step-down that shaves the payout if the timeline slips.³ The seller's headline number was $415. The realistic expected value was something well short of it.

The tender offer that never needed a vote: with a non-tradeable right and a two-step structure, holders couldn't cash out the promise or vote it down

The mechanics reinforce the point. J&J didn't run this as a merger requiring a shareholder vote; it ran a tender offer, and when roughly 57.1% of shares came in, it swept up the rest through a short-form merger under Section 251(h) of Delaware law - no stockholder vote at all.² Remaining holders were simply converted into the right to receive $380.00 plus a CVR.² And that CVR is non-tradeable: J&J's own materials stress it repeatedly, and the filing warns plainly that the milestones may never be achieved, in which case holders get nothing beyond the cash.¹³ So a holder skeptical of the sales target couldn't sell the right to a more optimistic buyer and lock in a value today. The $35.00 wasn't an asset you could price and exit. It was a bet you were required to hold to the end, on a game whose most important move belonged to the other side.

Isn't a sales milestone actually the seller's best friend?: the honest counter is that J&J had every incentive to hit the very number it would then have to pay on

The fair objection is that this reads too cynically. A sales milestone isn't a trap - it's aligned. J&J paid billions for Abiomed precisely because it wanted the Impella franchise to grow, so it has every commercial reason to drive sales past $3.7 billion whether or not a CVR is attached.³ If anything, the earn-out sharpens that incentive. And the clinical milestones are real: an FDA approval in a new patient population and a Class I guideline recommendation would expand the market on their own, which feeds the sales bar too.³⁴ All true - and yet the alignment is imperfect in exactly the ways that decide a $17.50 payout. J&J controls the timing, and the step-down means a target hit late costs it half.³ J&J controls pricing and portfolio emphasis, and a franchise can grow handsomely while still landing just under a specific threshold in a specific window. The buyer benefits from selling a lot of pumps; it benefits more from selling a lot of pumps while missing the precise bar that would trigger the payment. That gap - between growing the business and clearing the milestone - is the space where a well-drafted CVR quietly saves the acquirer money.

Strip the deal to its spine and the elegance is plain. J&J wrote a promise that looks generous at the ceiling and modest at the floor, marketed on the milestones that flatter the science, and weighted on the one number it would spend the next five years deciding how hard to chase. The sellers took $380.00 they could count and up to $35.00 they could only hope for - and handed the party writing the check the pen that would decide how much of the hope came true. The lesson isn't that the CVR was unfair. It's that in a contingent deal, the size of the number tells you almost nothing; the identity of whoever controls the milestone tells you everything.